The ONK Therapeutic Platform and its Intellectual Property (IP)

ONK Therapeutics has worked hard to develop a strong IP matrix of licences and patent filings to support its platform capabilities and the development of optimized NK cell-based products.

The ONK Therapeutics Platform Advantage is that by applying these various modifications to allogeneic NK cells, ONK provides a platform from which cell therapy products can be designed to optimally treat different types of cancer.

The IP portfolio today includes 10 in-house developed patent families, filed following a strategy that includes early European and US applications, accelerating prosecution where early grant is seen as a proof of the technology.

IP covering the ONK platform includes protection for NK cells expressing:

(1) chimeric antigen receptors (CARs) specific for cancer-associated antigens, e.g. CD19, CD38, CD96 and MUC-1,

(2) TRAIL variants,

(3) Fc receptors, and

(4) HLA-E receptors.

Other families protect:

(5) NK cells with reduced sensitivity to TRAIL-induced cell death, as well as

(6) NK cells with reduced expression of checkpoint inhibitory receptors.

Some of the company’s IP highlights is provided below.

Licenced IP

NK cell lines

  • Worldwide exclusive licence to the KHYG-1 NK cell line

TRAIL variants

  • Worldwide exclusive licence to a major DR5 TRAIL variant

In-house IP

NK cells expressing TRAIL variants

  • European patent granted (EP 3317401), with a priority date of 29 July 2015.
  • US patent granted (US 10,034,925), with a priority date of 29 July 2015.
  • Applications pending in Europe, US, Japan, China, Australia, Canada, Brazil, India, South Korea, Mexico, New Zealand, Hong Kong and Russia (based on WO 2017/017,184), with a priority date of 29 July 2015.

NK cells expressing CD38 CARs

  • European patent granted (EP 3454871), with a priority date of 9 December 2016.
  • Applications pending in Europe, US, Japan, China, Australia, Canada, Brazil, India, South Korea, Indonesia, Saudi Arabia, Mexico, Hong Kong and Russia (based on WO 2018/104,562), with a priority date of 9 December 2016.

NK cells with reduced checkpoint inhibitory receptor expression

  • Applications pending in Europe, US, Japan, China, Australia, Canada, Brazil, India, South Korea, Mexico, New Zealand, Hong Kong and Russia (based on WO 2017/017,184), with a priority date of 29 July 2015.

NK cells in combination with IL-6 antagonists

  • Applications pending in Europe, US, Japan, China, Australia, Canada, Brazil, India, South Korea, Indonesia, Saudi Arabia, Mexico, Hong Kong and Russia (based on WO 2018/104,554), with a priority date of 9 December 2016.

NK cells expressing MUC-1 CARs

  • International application pending (WO 2019/101,998), with a priority date of 24 November 2017.

KHYG-1 cells expressing high-affinity Fc receptors

  • International application pending (WO 2019/201,629), with a priority date of 19 April 2018.
  • US application pending (US 2019/321,402), with a priority date of 19 April 2018.

NK cells with increased resistance to TRAIL; High Potency NK Cells, NK Cells for Viral Infection; NK Cells for Lymphoma Therapy

  • Various pending (unpublished) applications

More Efficacious

  • Multiple mechanisms of killing
  • Multiple dose capability
  • Cancer-optimized therapies

Excellent Safety Profile

  • No uncontrolled expansion
  • Less likely to cause cytokine release syndrome

Batch Manufactured

  • Off the shelf product
  • Scaled manufacturing capability
  • Broad availability